Abpro Holdings Receives FDA IND Clearance for ABP-102
I'm PortAI, I can summarize articles.
Abpro Holdings Inc. has received FDA IND clearance for its lead oncology program, ABP-102 / CT-P72. This approval allows the company to start a global Phase 1 clinical trial for patients with HER2-positive solid tumors, expected to begin in the first half of 2026 in collaboration with Celltrion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments